Key Takeaways Neumora Therapeutics reported its experimental depression drug didn't meet expectations, and shares plunged.The ...

Patients who received the drug, called navacaprant, showed no more improvement in depressive symptoms than people who ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Happy New Year, biotech ...

Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...

In a statement, Neumora revealed that the KOASTAL-1 study missed its primary endpoint, with navacaprant failing to achieve a ...

Even the coroner specified that the self-inflicted death was an “adverse effect” of the antidepressant the man had been ...

Research shows that caffeine inhibits the action of some antibiotics, such as Avelox (moxifloxacin), Noroxin (norfloxacin), ...

For nearly 20 years, antidepressants have carried suicide risk warnings for young people. Now, experts are questioning if the ...

Antidepressants known as selective serotonin reuptake inhibitors, or SSRIs have been the first line of treatment for mood ...

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

Neumora's KOASTAL-1 study results show navacaprant missed key goals in major depressive disorder. Additional studies and ...

In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant ...